Article
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
The lancet. Gastroenterology & hepatology - 1 Jul 2017
Welzel Tania M, Asselah Tarik, Dumas Emily O, Zeuzem Stefan, Shaw David, Hazzan Rawi, Forns Xavier, Pilot-Matias Tami, Lu Wenjing, Cohen Daniel E, Feld Jordan J
Abstract excerpt
BACKGROUND: Clinical studies have shown high rates of sustained virological response (hepatitis C virus [HCV] RNA <15 IU/mL) at post-treatment week 12 (SVR12) in patients with genotype 1b infection with and without cirrhosis who received coformulated ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin, for 12 weeks. In this study, we aimed to assess 8-week treatment with ombitasvir,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.